Tony bologna

[Tony bologna @Cervone2Cervone]

@VSimonAbraham @Longroaderstar Thank you

[Mark C @MarkC_LVB]

Chief Academic Officer for Cardiology at Cleveland clinic also agrees that ASOs inferior to siRNA, at $ARWR discussion in June. Called RNAi and “No Brainer “ over ASOs

https://t.co/qL8eogRGWU

[Mark C @MarkC_LVB]

@3IDWarrant @TTRAmyloid He’ll need more than luck...

RE: $ARWR plozasiran vs $IONS olezarsen, Dr Nissen @ R&D event today “Well, this is a no-brainer really. You’ve got a drug that the ASO class has more AEs and shorter duration of action” also not as effective, who wants the ASO?

[Parin Vasava @Aartha4money]

$ARWR 🚀

[BioBoyScout @BioBoyScout]

New paper: The Forced Move - Part 3, Roche.

Roche sold Arrowhead its founding RNAi business in 2011. Buying it back now would mean paying a fortune to reclaim the science it once let go. $ARWR $RHHBY
https://t.co/NcDEz9EfXi

[Dirk Haussecker @RNAiAnalyst]

$arwr to enhance internal target discovery efforts, addressing prior dependence on others (from conference call).

[Dirk Haussecker @RNAiAnalyst]

$beam $bold for the kids in the last row not paying attention:

In the patent system, you disclose something so society has benefit of that knowledge; in return you get time-limited exclusivity and can license; it does not matter if the person receiving that knowledge feels he is better suited to finalize the product;

in addition to disclosure, biotech relies on trade secrets; when you change your employer, you cannot just take trade secrets with you; esp with $BEAM, which has been formed in the $alny mould, I'd be surprised if these trade secrets werent protected as part of a strict werent non-compete.

[Tony bologna @Cervone2Cervone]

@BioBoyScout Don't sell

[BioBoyScout @BioBoyScout]

New paper: The Forced Move - Part 1, Novartis.
A bit of game theory on why the partner that knows Arrowhead best is the one that can least afford to let a rival have it. $ARWR $NVS
https://t.co/bYC25GUfLM

[ArrowheadPharma @ArrowheadPharma]

What an incredible week in Chicago! Thank you to everyone who visited us at #NLASessions and #ENDO2026; the conversations and connections mean everything.

We’re leaving ready for what's next.

[ArrowheadPharma @ArrowheadPharma]

We're hosting Part I of our 2026 Summer Series of R&D Webinars beginning with a focus on our #Cardiometabolic pipeline!

Tune in to hear presentations from external experts and Arrowhead management.

Learn more: https://t.co/uDxZUpf7KW

[Tony bologna @Cervone2Cervone]

$ARWR
8 K
Dr Cohen appointment
I'm thinking this is very Bullish

[Tony bologna @Cervone2Cervone]

@Maximus_Holla Have fun

[BioBoyScout @BioBoyScout]

New paper: The Platform Gambit, Why Arrowhead Doesn't Need a Buyer
Most biotechs must sell. $ARWR is the rare exception: owns its mfg, has an approved drug, runs a platform deep enough to fund its own future.
The one who can walk away sets the price.
https://t.co/bkAKGLfDeq

[Stock Market Genius @stockmktgenius]

Arrowhead Pharmaceuticals surges 442% with massive 1.5M+ volume, price hits 70.73, huge momentum building!

Heating Up: Arrowhead Pharmaceuticals
Symbol: $ARWR
Price: 70.73
Volume: 1,546,383
% Up: 442%

[Ryan @yeck_ryan]

Putzing around 17 Mile today. Patiently waiting for $ARWR cardano:native and midnight-3:native to explode 📈

[Biotech FQ @BiotechFQ]

Another good White paper for $ARWR from @BioBoyScout Arrowhead’s #AI Edge Isn’t the AI, It’s the Data
I found it interesting both for the shared $ARWR insight and #AI discussed for drug development, but quality #Data is key within drug development.
https://t.co/lDCakWIhkE

[Brock’s Stocks @BrocksStocks1]

Watchlist for Monday $SNOW $ARWR $JCI $POWL $DDOG

[ArrowheadPharma @ArrowheadPharma]

The work in Chicago continues with #ENDO2026 June 13–16! 🌆

Find us at Booth #3719 to learn more about our data and what we're working on!

Come say hello; we look forward to connecting!